PT  - JOURNAL ARTICLE
AU  - Giulia Russo
AU  - Marzio Pennisi
AU  - Marco Viceconti
AU  - Francesco Pappalardo
TI  - In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform
AID  - 10.1101/2020.05.06.080630
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.05.06.080630
4099  - http://biorxiv.org/content/early/2020/05/07/2020.05.06.080630.short
4100  - http://biorxiv.org/content/early/2020/05/07/2020.05.06.080630.full
AB  - SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. Here, we present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.